Quantification of levetiracetam in human plasma by liquid chromatography–tandem mass spectrometry: Application to therapeutic drug monitoring

Abstract

A rapid, selective, reliable, precise, accurate, and reproducible tandem mass spectrometric (MS-MS) method for the quantification of levetiracetam (LEV) in human plasma using adenosine as an internal standard (IS) has been developed and validated. The drug and IS were extracted by solid phase extraction (SPE) technique and analyzed on Symmetry ® C 18 column (5 μm, 3.9 mm × 50 mm) using a mobile phase of methanol–water–formic acid (97:03:0.25, v/v/v) at a flow rate of 0.2 ml/min. Quantitation was achieved using a positive electrospray ionization (ESI+) interface employing multiple reaction monitoring (MRM) mode at MRM transitions m/ z 171 > 126 and m/ z 268 > 136 for LEV and IS, respectively. The method was validated over the concentration range of 1.0–40 μg/ml ( r > 0.99) with a limit of quantification of 1.0 μg/ml (R.S.D.%; 4.1 and Bias%; −9.0 to + 11.0%). Intra- and inter-run precision of LEV assay at three concentrations ranged from 0.6 to 8.9% with accuracy (bias) varied from −4.0 to 8.6% indicating good precision and accuracy. Analytical recoveries of LEV and IS from spiked human plasma were in the range of 91.7–93.4% and 80.2–84.1%, respectively. Stability of LEV in human plasma samples at different conditions showed that the drug was stable under the studied conditions. Matrix effect study showed a lack of matrix effect on mass ions of LEV and IS. The described method compared well with the commercial HPLC-UV method of Chromsystem ( r 2 = 0.99). The suitability of the developed method for therapeutic drug monitoring was demonstrated by measuring LEV in human plasma samples of epileptic patients treated with LEV.